title: Phase II trial of fludarabine phosphate in advanced renal cell carcinoma: an Illinois Cancer Council Study.
abstract: Fludarabine Phosphate (FP), the 2-fluoro, 5'phosphate derivative of adenosine arabinoside (ara-A), was studied in 18 patients with advanced renal cell carcinoma. These patients had measurable disease and had not received chemotherapy. FP was administered at a loading dose of 20 mg/m2 followed by a 48-hour infusion at 30 mg/m2/day given every 21 days. There were no complete or partial responses seen. Toxicity was mainly hematologic, with leukopenia most commonly observed. FP given in this manner had no activity in advanced renal cell carcinoma.
authors: University of Illinois, Chicago.
authors: D H
authors: DH
authors: Shevrin
authors: T E
authors: TE
authors: Lad
authors: L J
authors: LJ
authors: Kilton
authors: M A
authors: MA
authors: Cobleigh
authors: R R
authors: RR
authors: Blough
authors: L L
authors: LL
authors: Weidner
authors: N J
authors: NJ
authors: Vogelzang
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000964:Antimetabolites, Antineoplastic / Q000009:adverse effects / Q000627:therapeutic use*; D001088:Arabinonucleotides / Q000627:therapeutic use*; D002292:Carcinoma, Renal Cell / Q000188:drug therapy*; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D007680:Kidney Neoplasms / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D001084:Vidarabine Phosphate / Q000009:adverse effects / Q000031:analogs & derivatives / Q000627:therapeutic use*
chemical_list: D000964:Antimetabolites, Antineoplastic; D001088:Arabinonucleotides; D001084:Vidarabine Phosphate; C042382:fludarabine phosphate